price down icon1.33%   -0.27
after-market  After Hours:  19.56  -0.42   -2.10%
10x Genomics Inc stock is currently priced at $19.98, with a 24-hour trading volume of 955.52K. It has seen a -1.33% decreased in the last 24 hours and a -20.11% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $19.96 pivot point. If it approaches the $20.58 resistance level, significant changes may occur.
Previous Close:
24h Volume:
Market Cap:
Net Income/Loss:
P/E Ratio:
Net Cash Flow:
1W Performance:
1M Performance:
6M Performance:
1Y Performance:
1D Range:
52W Range:

10x Genomics Inc Stock (TXG) Company Profile

10x Genomics Inc
925 401 7300
6230 Stoneridge Mall Road, Pleasanton, CA
Next Earnings Date
Latest SEC Filings
TXG's Discussions on Twitter

10x Genomics Inc Stock (TXG) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-14-23 Initiated Guggenheim Buy
Dec-13-23 Initiated Wolfe Research Outperform
Dec-12-23 Upgrade BofA Securities Underperform → Neutral
Jul-05-23 Resumed JP Morgan Overweight
May-10-23 Initiated Barclays Overweight
Mar-31-23 Initiated Stephens Overweight
Feb-02-23 Initiated UBS Neutral
Dec-14-22 Initiated Deutsche Bank Buy
Aug-18-22 Downgrade Goldman Neutral → Sell
Jul-25-22 Initiated Canaccord Genuity Buy
Jul-15-22 Downgrade BofA Securities Neutral → Underperform
Jul-15-22 Downgrade William Blair Outperform → Mkt Perform
Oct-15-21 Resumed Cowen Outperform
Sep-14-21 Downgrade BofA Securities Buy → Neutral
Mar-15-21 Initiated William Blair Outperform
Dec-02-20 Initiated Goldman Neutral
Sep-09-20 Initiated Morgan Stanley Overweight
Jul-10-20 Initiated Stifel Buy
Mar-05-20 Initiated Guggenheim Buy
Jan-07-20 Initiated Citigroup Buy
Oct-07-19 Initiated BofA/Merrill Buy
Oct-07-19 Initiated Cowen Outperform
Oct-07-19 Initiated JP Morgan Overweight
Sep-24-19 Initiated Evercore ISI Outperform
View All

10x Genomics Inc Stock (TXG) Financials Data

10x Genomics Inc (TXG) Revenue 2024

TXG reported a revenue (TTM) of $625.45 million for the quarter ending March 31, 2024, a +16.64% rise year-over-year.

10x Genomics Inc (TXG) Net Income 2024

TXG net income (TTM) was -$264.30 million for the quarter ending March 31, 2024, a -51.61% decrease year-over-year.

10x Genomics Inc (TXG) Cash Flow 2024

TXG recorded a free cash flow (TTM) of -$73.95 million for the quarter ending March 31, 2024, a +41.19% increase year-over-year.

10x Genomics Inc (TXG) Earnings per Share 2024

TXG earnings per share (TTM) was -$2.23 for the quarter ending March 31, 2024, a -45.75% decline year-over-year.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics, including the physical organization of DNA; single cell CNV for measuring cellular heterogeneity through DNA changes, such as copy number variation; and visium spatial gene expression solution that measures the spatial gene expression patterns across a tissue sample. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. 10x Genomics, Inc. was founded in 2012 and is headquartered in Pleasanton, California.
health_information_services EVH
price up icon 0.00%
price down icon 1.00%
price down icon 1.41%
health_information_services WAY
price down icon 1.73%
price down icon 5.96%
health_information_services RCM
price down icon 0.48%
Cap:     |  Volume (24h):